Table 1 Summary of characteristics of included studies of prevalence of EDs in children
Author | Year | Study Type | risk of bias | type of Disorders | instrument | Age range or average | Prevalence of EDs in children (%) | Sample size | Country |
|---|---|---|---|---|---|---|---|---|---|
Lieberman et al.[18] | 2019 | Cross-sectional | Low | AN | EDI-Ca | 8 to 13(11.27 ± 0.9) | 72.6 | 106 | Canada |
Lieberman et al.[18] | 2019 | Cross-sectional | Low | ARFID | EDI-C | 8 to 13(11.27 ± 0.9) | 27.4 | 106 | Canada |
Mohammadi et al.[19] | 2020 | Cross-sectional | Low | AN | DSM-IV K-SADS-PLb | 6 to 9 | 0 | 9274 | Iran |
Mohammadi et al.[19] | 2020 | Cross-sectional | Low | BN | DSM-IV K-SADS-PL | 6 to 9 | 0.01 | 9274 | Iran |
Mohammadi et al.[19] | 2020 | Cross-sectional | Low | BED | DSM-IV K-SADS-PL | 6 to 9 | 0.05 | 9274 | Iran |
Mohammadi et al.[19] | 2020 | Cross-sectional | Low | OSFED | DSM-IV K-SADS-PL | 6 to 9 | 0.11 | 9274 | Iran |
BORTES et al.[20] | 2022 | prospectively | Low | ED | ICD- 10c | ……… | 0.98 | 266,664 | Sweden |
Allen et al.[21] | 2008 | population-based cohort | Moderate | BED | ChEDEd | 8 to 13 | 5.19 | 154 | Australia |
Amos-Kroohs et al.[16] | 2016 | Cross-sectional | Low | Pica | A 6-page questionnaire | 9.43 ± 0.45 | 0 | 81 | USA |
Amos-Kroohs et al.[16] | 2016 | Cross-sectional | Low | Pica | A 6-page questionnaire | 9.43 ± 0.45 | 0 | 81 | USA |
Amos-Kroohs et al.[16] | 2016 | Cross-sectional | Low | BN | A 6-page questionnaire | 9.43 ± 0.45 | 0 | 81 | USA |
Amos-Kroohs et al.[16] | 2016 | Cross-sectional | Low | AN | A 6-page questionnaire | 9.43 ± 0.45 | 0 | 81 | USA |
Convertino & Blashill[22] | 2021 | Longitudinal study | Low | AN | KSADS- 5e | 9 to 10 | 0.1 | 11,718 | USA |
Convertino & Blashill[22] | 2021 | Longitudinal study | Low | BN | KSADS- 5 | 9 to 10 | 0.1 | 11,718 | USA |
Convertino & Blashill[22] | 2021 | Longitudinal study | Low | BED | KSADS- 5 | 9 to 10 | 0.8 | 11,718 | USA |
Convertino & Blashill[22] | 2021 | Longitudinal study | Low | OSFED BN | KSADS- 5 | 9 to 10 | 0.1 | 11,718 | USA |
Convertino & Blashill[22] | 2021 | Longitudinal study | Low | OSFED BED | KSADS- 5 | 9 to 10 | 0.6 | 11,718 | USA |
Hartmann et al.[12] | 2018 | Cross-sectional | Low | Pica | EDY-Qf | 7 to 14 | 4.98 | 804 | Germany |
Hartmann et al.[12] | 2018 | Cross-sectional | Low | RD | EDY-Q | 7 to 14 | 1.49 | 804 | Germany |
Hartmann et al.[12] | 2018 | Cross-sectional | Low | ARFID | EDY-Q | 7 to 14 | 3.11 | 804 | Germany |
Wong et al.[23] | 2011 | Prospective cohort | Moderate | ED | ChEATg | 10& 12 | 10.6 | 705 | Taiwan |
Al Agroudi et al.[6] | 2023 | case–control | Low | AN | DSM- 5 | 6 to 12 | 0.6 | 528 | Egypt |
Al Agroudi et al.[6] | 2023 | case–control | Low | ARFID | DSM- 5 | 6 to 12 | 2.5 | 528 | Egypt |
Al Agroudi et al.[6] | 2023 | case–control | Low | BED | DSM- 5 | 6 to 12 | 5.7 | 528 | Egypt |
Al Agroudi et al.[6] | 2023 | case–control | Low | NES | DSM- 5 | 6 to 12 | 0.8 | 528 | Egypt |
Al Agroudi et al.[6] | 2023 | case–control | Low | Pica | DSM- 5 | 6 to 12 | 0.2 | 528 | Egypt |
Al Agroudi et al.[6] | 2023 | case–control | Low | RD | DSM- 5 | 6 to 12 | 0.4 | 528 | Egypt |
Al Agroudi et al.[6] | 2023 | case–control | Low | OSFED | DSM- 5 | 6 to 12 | 2.9 | 528 | Egypt |
Smith & Mason[24] | 2022 | Cross-sectional | Low | BED | K-SADS | 9 to 10 | 0.1 | 7793 | US |
Nagata et al.[25] | 2021 | Prospective cohort | Low | BED | KSADS- 5 | 9 to 10(9.95 ± 0.63) | 0.7 | 11,025 | US |
Lamerz et al.[25] | 2005 | cross-sectional | Low | BED | DSM-IV | 5 to7(5.8 ± 4) | 2 | 1979 | Germany |
Lamerz et al.[25] | 2005 | cross-sectional | Low | NES | DSM-IV | 5 to7(5.8 ± 4) | 1.1 | 1979 | Germany |
Papini et al.[26] | 2024 | Longitudinal | Moderate | Pica | Asking related questions to the mother | 3 | 2.29 | 9881 | UK |
Smith et al.[27] | 2023 | Prospective cohort | Low | BED | KSADS- 5 | 9 to 10 | 0.8 | 9438 | US |
Smith et al.[27] | 2023 | Prospective cohort | Low | SBED | KSADS- 5 | 9 to 10 | 0.6 | 9438 | US |
Olfson et al.[7] | 2023 | Cross-sectional | Low | BED | KSADS for DSM- 5 | 9 to 10 | 0.66 | 11,874 | US |
Olfson et al.[7] | 2023 | Cross-sectional | Low | OED | KSADS for DSM- 5 | 9 to 10 | 0.07 | 11,874 | US |
Ayaz et al.[28] | 2012 | Cross-sectional | Low | ED | ECI- 4 h | 3 to5 | 2.9 | 34 | Turkey |
Shapiro et al.[29] | 2007 | Cross-sectional | Low | BED | C-BEDSi&SCIDj | 5 to 13(8.7 ± 2.2) | 9 | 55 | US |
Shapiro et al.[29] | 2007 | Cross-sectional | Low | SBED | C-BEDS&SCID | 5 to 13(8.7 ± 2.2) | 22 | 55 | US |
Dursun et al.[17] | 2020 | Cross-sectional | Low | ED | DAWBAk | 8.23 ± 0.77 | 0 | 1080 | Turkey |
Dursun et al.[17] | 2020 | Cross-sectional | Low | SED | DAWBA | 8.23 ± 0.77 | 0.1 | 1080 | Turkey |
Chong et al.[13] | 2017 | Cross-sectional | Low | ED | ChEAT | 10 to 11 | 30.8 | 816 | Malaysi |